Essilor International Sa-adr Stock Earnings Reports

EssilorLuxottica reported a strong 2025 with revenue up 11% for the full year (Q4 +18% at constant currency) and record free cash flow of EUR 2.8bn. Management reiterated a strategic pivot from a traditional optical company to a med‑tech and data‑driven group, with AI/wearable glasses and oculomics at the core of future growth. In 2025 the group sold >7 million AI glasses, driven by Ray‑Ban and Oakley, and management expects wearables to scale further across wholesale and its 18,000‑store retail footprint. Myopia management (Stellest and other technologies) grew ~22% and Stellest is positioned as a clinical/medical treatment (FDA authorization for Stellest 1.0 in the U.S.); rollouts of Stellest 2.0 in EMEA and filings for the U.S. are underway. Gross margin was down ~260 bps YoY due to a mix effect (AI glasses) and a tariff headwind (estimated ~1/3 of the margin impact from tariffs, ~2/3 from AI glasses dilution). Operating profit margin was slightly lower (70 bps at constant FX), while net debt/EBITDA stood at ~1.7x. Management plans continued upfront OpEx/CapEx investments to capture scale in wearables, hearing‑aid integrations and med‑tech M&A (targeting medical AI and diagnostics), while reaffirming a 5‑year outlook targeting broadly aligned revenue and operating profit growth. Short‑term considerations: FX (USD weakness vs EUR) and tariff annualization may pressure 2026 reported results; management expects production capacity to be rampable via existing plants and partners and emphasizes long‑term margin improvement from price/mix, scale and lens/add‑on attachments.